Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms AMBER
- Sponsors AbbVie
- 06 Apr 2017 Planned number of patients changed from 700 to 600.
- 06 Apr 2017 Planned End Date changed from 1 Nov 2018 to 1 Oct 2017.
- 06 Apr 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Oct 2017.